AiM  Vol.3 No.1 , March 2013
A Single Blind Comparative Randomized Non-Inferior Multicenter Study for Efficacy and Safety of Levofloxacin versus Ciprofloxacin in the Treatment of Uncomplicated Typhoid Fever
Abstract: Ciprofloxacin is currently the drug of choice for typhoid fever, but Salmonella typhi resistance to ciprofloxacin is increasing, while levofloxacin has been shown to be very effective in a few open studies. This study aimed to compare the efficacy, and safety of levofloxacin and ciprofloxacin for typhoid fever. From 110 patients with confirmed typhoid fever, 54 patients received oral levofloxacin 500 mg once daily with one drop out, while 56 received ciprofloxacin 500 mg twice daily for 7 days with two drop outs. Defervescence of fever was achieved on an average of 3 days after initiating levofloxacin and 5 days after starting ciprofloxacin and one microbiologically non confirmed typhoid fever relapse occurred in the levofloxacin group while two relapses with positive Salmonella microorganism occurred in the ciprofloxacin group. No carrier of Salmonella typhi was found in both groups at day 30. Adverse reactions were more pronounced in the ciprofloxacin group compared to the levofloxacin group. In conclusion, oral levofloxacin 500 mg once daily for one week showed faster fever clearance compared to ciprofloxacin 500 mg twice daily in typhoid fever in Indonesia, and less adverse reactions occurred with levofloxacin compared to ciprofloxacin. This electronic document is a “live” template. The various components of your paper (title, text, heads, etc.) are already defined on the style sheet, as illustrated by the portions given in this document.
Cite this paper: R. Nelwan, K. Chen Lie, S. Hadisaputro, E. Suwandoyo, S.  , N.  , H. Yusuf, P. Sudjana, G. Ismanoe, D. Djunaedi, H. Mubin, M. Said and D. Paramita, "A Single Blind Comparative Randomized Non-Inferior Multicenter Study for Efficacy and Safety of Levofloxacin versus Ciprofloxacin in the Treatment of Uncomplicated Typhoid Fever," Advances in Microbiology, Vol. 3 No. 1, 2013, pp. 122-127. doi: 10.4236/aim.2013.31019.

[1]   J. A. Crump, S. P. Luby and E. D. Mintz, “The Global Burden of Typhoid Fever,” Bull World Health Organization, 2004, pp. 346-353.

[2]   R. Chandra, S. Srinivasan, P. Nalini and R. S. Rao, “Multidrug Resistant Enteric Fever,” Journal of Tropical Medicine & Hygiene, Vol. 95, 1992, pp. 284-287.

[3]   E. Braunwald, A. S. Fauci, D. L. Kasper, S. L. Hauser, D. L. Longo and J. L. Jameson, “Harrison’s Manual of Medicine,” McGraw-Hill, New York, 2012.

[4]   E. J. Threlfall and L. R.Ward, “Decreased Susceptibility of Ciprofloxacin in Salmonella Enterica Serovar Typhi,” Emerging Infectious Diseases, Vol. 7, 2001, pp. 448-450.

[5]   K. Hirose, K. Tamura, H. Sagara and H. Watanabe, “Antibiotic Susceptibility of Salmonella Enterica Serovar Paratyphi A Isolated from Patients in Japan,” Journal of Antimicrobial Chemotherapy, Vol. 45, No. 3, 2001, pp. 956-958. doi:10.1128/AAC.45.3.956-958.2001

[6]   T. Dimitrov, E. E. Udo, O. Albaksami, S. Al-Shehab, A. Kilani, M. Shehab and A. Al-Nakkas, “Clinical and Microbiological Investigation of Typhoid Fever in an Infectious Disease Hospital in Kuwait,” Journal of Antimicrobial Chemotherapy, Vol. 56, No. 4, 2007, pp. 538-544. doi:10.1099/jmm.0.46814-0

[7]   R. H. H. Nelwan, “Ciprofloxacin Resistance Typhoid Fever in Indonesia,” 10th Edition, Congress of Tropical Malaria, Nagasaki, 1996.

[8]   S. Chitnis, V. Chitnis, N. Hemvani and D. S. Chitnis, “Ciprofloxacin Therapy for Typhoid Fever Needs Reconsideration,” Journal of Infection and Chemotherapy, Vol. 12, No. 6, 2006, pp. 402-404. doi:10.1007/s10156-006-0472-9

[9]   H. A. Vinh, J. Wain, T. N. Vo, N. N. Cao, T. C. Mai and D. Bethell, “Two or Three Days of Ofloxacin Treatment for Uncomplicated MDR Typhoid Fever in Children,” Antimicrobial Agents and Chemotherapy, Vol. 40, No. 4, 1996, pp. 958-961.

[10]   R. H. H. Nelwan, K. C. Lie and N. D. Paramita, “Open Study on Efficacy and Safety of Levofloxacin in the Treatment of Uncomplicated Typhoid Fever,” Journal of Tropical Medicine, Vol. 37, 2006, pp. 126-130.

[11]   R. H. H. Nelwan, “Clinical Score for Diagnosis of Typhoid Fever,” Majalah Dokter Keluarga, Vol. 10, No. 4, 1991, pp. 17-21.

[12]   A. Haque, N. Ahmed, A. Peerzada, A. Raza, S. Bashir and G. Abbas,“Utility of PCR in Diagnostic of Problematic Cases of Typhoid,” Japanese Journal of Infectious Diseases, Vol. 54, 2001, pp. 237-239.

[13]   M. Levine, O. Grados and R. H. Gilman, “Diagnostic Value of the Widal Test in Area Endemic for Typhoid Fever,” American Journal of Tropical Medicine and Hygiene, Vol. 27, 1978, pp. 795-810.

[14]   T. Pang and S. D. Puthucheary, “Significance of Widal Test in the Diagnosis of Typhoid Fever in an Endemic Area,” Journal of Clinical Pathology, Vol. 36, No. 4, 1983, pp. 471-475. doi:10.1136/jcp.36.4.471

[15]   R. Davis and H. M. Bryson, “Levofloxacin: A Review of Its Antibacterial Activity, Pharmacokinetics and Therapeutic Efficacy,” Drugs, Vol. 47, No. 4, 1994, pp. 677-710. doi:10.2165/00003495-199447040-00008

[16]   K. F. Croom and K. L. Goa, “Levofloxacin: A Review of Its Use in the Treatment of Bacterial Infections,” Pharmacokinetic Properties, Drugs, Vol. 64, 2003, pp. 2780-2782.

[17]   J. Zheng, Z. Yuy and M. G. Wei, “Clinical Study in the Evaluation of Levofloxacin in the Treatment of Typhoid and Paratyphoid Fever,” ISC Congress, Sydney, No. 3310, 1997, p. 100.

[18]   R. H. H. Nelwan, H. I. Zulkarnain, J. Gunawan, Y. Supandiman and H. Yusuf, “A Comparative Study of Short Course Ciprofloxacin Treatment in Typhoid and Paratyphoid Fever,” Drugs, Vol. 49, No. S2, 1995, pp. 463-465. doi:10.2165/00003495-199500492-00136

[19]   M. Velmonte, A. David and M. Bernardo, “Randomized Controlled Safety and Efficacy Study Comparing Ofloxacin with Chloramphenicol in the Treatment of Salmonella Enteric Fever,” World Scientific Co., Singapore City, 1992.

[20]   B. A. Lipsky and C. A. Baker, “Fluoroquinolones Toxicity Profile,” Clinical Infectious Diseases, Vol. 28, No. 2, 1999, pp. 352-364. doi:10.1086/515104

[21]   K. A. Rodvald, “Clinical Safety Profile of Fluoroquionolones,” Penetration, 2006, pp. 34-40.

[22]   R. H. H. Nelwan, A. W. Hendarwanto, I. Zulkarnain and J. Gunawan, “Double-Blind Randomized Controlled Study of Once Daily 400 mg Pefloxacin in Typhoid and Paratyphoid Fever,” Medical Journal of the Univiversity of Indonesia, Vol. 3, 1994, pp. 38-41.

[23]   R. H. H. Nelwan, B. W. Hendarwanto, I. Zulkarnain and J. Gunawan, “A Controlled Study of Ofloxacin in Typhoid Fever,” Majalah Kesehatan Masyarakat Indonesia, Vol. 22, 1995, pp. 58-65.

[24]   R. H. H. Nelwan, B. Setiawan, J. Gunawan and H. I. Zulkarnain, “Short Course Fleroxacin in Typhoid Fever,” Acta Medica Indonesia, Vol. 30, 1998, pp. 25-30.